US006541041B1

(12) **United States Patent**
Konishi

(10) **Patent No.: US 6,541,041 B1**
(45) **Date of Patent: Apr. 1, 2003**

(54) **CRUDE DRUG EXTRACTS, AND METHODS FOR MAKING AND STANDARDIZING SAME**

(75) Inventor: **Jin-emon Konishi**, Musashino (JP)

(73) Assignee: **Nippon Zoki Pharmaceutical Co., Ltd.**, Osaka (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/492,118**

(22) Filed: **Jan. 27, 2000**

Related U.S. Application Data

(62) Division of application No. 09/200,918, filed on Nov. 30, 1998.

(30) **Foreign Application Priority Data**

Nov. 28, 1997 (JP) 9-344345

(51) **Int. Cl.**[7] **A61K 35/78**

(52) **U.S. Cl.** **424/725**; 424/724; 424/520

(58) **Field of Search** 424/195.1, 520, 424/724, 725

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,959,566	A	5/1976	Pangonis
4,036,787	A	7/1977	Blount
4,039,474	A	8/1977	Feistel et al.
4,056,937	A	11/1977	Suzuki
4,089,883	A	5/1978	Blount
4,138,421	A	2/1979	Blount
4,145,415	A	3/1979	Sato
4,863,518	A	9/1989	Blount
4,985,254	A	1/1991	Konishi et al.
4,985,354	A	1/1991	Toyomaki et al.
5,013,558	A	5/1991	Konishi
5,057,324	A	10/1991	Shibayama et al.
5,127,994	A	7/1992	Johansson
5,227,089	A	7/1993	Hasegawa et al.
5,534,509	A	7/1996	Konishi et al.
5,560,935	A	10/1996	Konishi et al.
5,658,896	A	8/1997	Konishi et al.
5,767,103	A	6/1998	Greenberg et al.
5,807,951	A	9/1998	Konishi et al.

FOREIGN PATENT DOCUMENTS

EP	0 315 591	A2	5/1989
EP	0 315 591		10/1989
EP	0341209	A2	11/1989
EP	0 348 353	A2	12/1989
EP	0 621 038	A1	10/1994
EP	0 645 142	A1	3/1995
EP	0 733 636	A1	9/1996
FR	2 610 523		8/1988
FR	2 671 488		7/1992
GB	697351		9/1953
GB	0 300 973		4/1989
JP	53-101515		9/1978
JP	57-77697		5/1982
JP	57-183720		11/1982
JP	58-35117		3/1983
JP	58-121217		7/1983
JP	63-25600		5/1988
JP	63-039572		8/1988
JP	3-43279		7/1991
JP	3-204803		9/1991
JP	2594222		12/1996
JP	62-145022		6/1997
WO	WO 93/08828		5/1993

OTHER PUBLICATIONS

Boltz et al. Analytical Chemistry (1947), vol. 19, No. 11, pp. 873–877.*

Steranka et al., "Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions." *Proc Natl Acad Sci USA*,, May 1988, 85(9):3245–9.

Galvez et al., "Antidiarrhoeic activity of Euphorbia hirta extract and isolation of an active flavonoid constituent." *Plant Med*, Aug. 1993, 59(4):33–6.

Hamada et al., "Free radical scavenging action of baicalein.", *Arch Biochem Biphys*., Oct. 1993, 306(1):261–6.

Xu et al., "Immunological mechanisms of antitumor activity of some kinds of crude drugs on tumor necrosis factor production." *Int J Immunopharmacol*, 1989, 11(6):607–13.

Habib et al., "Difference spectrophotometric estimation of santonin", *J Assoc Off Anal Chem*, Sep.–Oct. 1984, 67(5):939–41.

Lin et al., "Medicinal plants used for the treatment of hepatitis in Taiwan", *Am J Chin Med*, 1990, 18(1–2):35–43.

Lin et al., "The anti–flammatory effects of Chinese crude drug prescriptions on experimental arthritis.", *Am J. Chin Med*, 1995, 23(2):145–52.

Takeoka, Y. et al., "Influence of Neurotropin on Thymic Microenvironmental Abnormalities of NZB Mice," *Int. J. Immunotherapy*, XI(2), pp. 49–56 (1995).

"Drugs in Japan, Ethical Drugs," Yakugyo Jiho Co., Ltd., 1994, p. 1434.

(List continued on next page.)

Primary Examiner—Francisco Prats
Assistant Examiner—Susan D. Coe
(74) *Attorney, Agent, or Firm*—Hollander Law Firm, P.L.C.

(57) **ABSTRACT**

Crude drug extracts containing soluble silicon compounds as an effective component are obtained by subjecting a crude drug to extraction with water or an aqueous solvent, preferably at an alkaline pH. The crude drugs subjected to extraction to obtain the extracts may be derived from animals, plants, etc. The quality of the crude drug extract can be standardized using the soluble silicon compounds as an index. The soluble silicon compounds exhibit inhibitory action towards the production of plasma kallikrein. The amount of soluble silicon compounds in the dry extract may be used as an index whereby the quality of various crude drugs can be standardized which contributes to providing crude drug extracts having a stable or consistent quality. Consequently, the present invention greatly contributes to the appropriate standardization of pharmaceuticals.

13 Claims, No Drawings